المؤلفون: Barbara Rewerska, MD, Lawrence D. Sher, MD, Sady Alpizar, MD, Sylvia Pauser, MD, Grazyna Pulka, MD, Neelufar Mozaffarian, MD, PhD, Yacine Salhi, PhD, Camille Martinet, MS, Wafaa Jabert, MS, Girish Gudi, PhD, Vinu CA, MPharm, MSc, Sunitha GN, PhD, Julie Macoin, MSc, Victor Anstett, MS, Riccardo Turrini, PhD, Marie-Agnès Doucey, PhD, Stanislas Blein, PhD, Cyril Konto, MD, Martina Machkova, MD

المصدر: Journal of Allergy and Clinical Immunology: Global, Vol 3, Iss 1, Pp 100195- (2024)

مصطلحات موضوعية: Atopic dermatitis, anti-OX40 receptor, humanized monoclonal antibody, phase 2, telazorlimab, Immunologic diseases. Allergy, RC581-607

وصف الملف: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2772829323001200; https://doaj.org/toc/2772-8293

URL الوصول: https://doaj.org/article/f0ee145bd815434e8dd240eedfceb966